Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Daurismo (glasdegib)
i
Other names:
PF-04449913, PF 04449913, PF04449913, PF 04, PF-4449913, PF 4449913, PF4449913, PF-04, PF04
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Pfizer
Drug class:
Hedgehog cell-signalling pathway inhibitor, SMO protein inhibitor
Related drugs:
‹
vismodegib (14)
sonidegib (11)
GANT61 (2)
cyclopamine (2)
IPI 926 oral (2)
GANT1 (1)
BMS-833923 (0)
GT1708F (0)
Oxy210 (0)
SUBA-itraconazole (0)
IPI-926 topical (0)
ENV 101 (0)
ZSP1602 (0)
vismodegib (14)
sonidegib (11)
GANT61 (2)
cyclopamine (2)
IPI 926 oral (2)
GANT1 (1)
BMS-833923 (0)
GT1708F (0)
Oxy210 (0)
SUBA-itraconazole (0)
IPI-926 topical (0)
ENV 101 (0)
ZSP1602 (0)
›
Associations
(1)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia (NCT04231851)
Phase 2
University of California, Irvine
University of California, Irvine
Recruiting
Phase 2
University of California, Irvine
Recruiting
Last update posted :
02/05/2024
Initiation :
02/19/2020
Primary completion :
06/01/2024
Completion :
09/30/2025
NPM1 • CEBPA
|
NPM1 mutation
|
Vyxeos (cytarabine/daunorubicin liposomal formulation) • Daurismo (glasdegib)
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia (NCT03390296)
Phase 1/2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Completed
Phase 1/2
M.D. Anderson Cancer Center
Completed
Last update posted :
09/04/2023
Initiation :
12/27/2017
Primary completion :
02/04/2022
Completion :
02/04/2022
BCL2
|
Venclexta (venetoclax) • Bavencio (avelumab) • azacitidine • Mylotarg (gemtuzumab ozogamicin) • Daurismo (glasdegib) • ivuxolimab (PF-04518600)
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation (NCT04655391)
Phase 1b
City of Hope Medical Center
City of Hope Medical Center
Withdrawn
Phase 1b
City of Hope Medical Center
Withdrawn
Last update posted :
06/09/2022
Initiation :
06/25/2022
Primary completion :
12/15/2023
Completion :
12/15/2023
FLT3 • ABL1 • BCR • IDH1 • AXL
|
IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836
|
Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • Bosulif (bosutinib) • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome (BRIGHT AML) (NCT01546038)
Phase 1b/2
Pfizer
Pfizer
Completed
Phase 1b/2
Pfizer
Completed
Last update posted :
03/03/2020
Initiation :
06/27/2012
Primary completion :
01/03/2017
Completion :
03/04/2019
RUNX1
|
decitabine • daunorubicin • Daurismo (glasdegib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login